Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Posted by ABMN Staff on Apr 8th, 2025

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a research report report published on Monday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 1.4 %

Shares of BTX opened at $5.52 on Monday. The business’s 50-day moving average price is $4.53 and its 200 day moving average price is $2.03. The stock has a market capitalization of $324.72 million, a P/E ratio of -2.43 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1-year low of $5.10 and a 1-year high of $8.31.

Brooklyn ImmunoTherapeutics Announces Dividend

The company also recently declared a monthly dividend, which was paid on Monday, March 31st. Investors of record on Friday, March 14th were given a $0.0862 dividend. The ex-dividend date was Friday, March 14th. This represents a $1.03 annualized dividend and a dividend yield of 18.73%. Brooklyn ImmunoTherapeutics’s dividend payout ratio (DPR) is presently -38.33%.

Brooklyn ImmunoTherapeutics Company Profile

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.